Jörg Vollmer, previously chief executive of Nexigen GmbH and a trained immunobiologist, has been named chief scientific officer of Rigontec GmbH, which is developing RNA-based immunotherapies for cancer. Dr Vollmer will lead Rigontec’s programmes in oncology and infectious disease. He studied biology at the Albert-Ludwigs-University in Freiburg and received a Phd from the Max-Planck-Institute of Immunobiology at the Department for Cellular Immunology in Freiburg.
Rigontec announced the appointment on 15 November 2016.
Copyright 2016 Evernow Publishing Ltd